COVID-19 and return to campus information.
University of California, Riverside
Phase 2 study investigates efficacy of the drug ecopipam developed by Emalex Biosciences Inc.
UC Riverside-led open-label pilot study leads to a double-blind clinical trial to further test ecopipam’s efficacy and safety in adult patients who stutter
UC Riverside biomedical scientist’s decades-long work moves to clinical trials